Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from WuXi AppTec Co., Ltd. Class H ( (HK:2359) ).
WuXi AppTec Co., Ltd. has completed the disposal of its subsidiaries, WuXi Clinical and WuXi MedKey, to Hillhouse, receiving an initial payment of RMB1.54 billion. This transaction is expected to generate a net profit of approximately RMB0.96 billion, significantly impacting the company’s financials by contributing over 10% of its net profit for the year 2024.
The most recent analyst rating on (HK:2359) stock is a Buy with a HK$114.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.
More about WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. is a joint stock company incorporated in China, operating in the healthcare industry. It provides comprehensive laboratory and manufacturing services to support the pharmaceutical, biotechnology, and medical device industries.
Average Trading Volume: 5,839,120
Technical Sentiment Signal: Buy
Current Market Cap: HK$303.6B
For detailed information about 2359 stock, go to TipRanks’ Stock Analysis page.